Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
1.470
-0.030 (-2.00%)
At close: Mar 3, 2026, 4:00 PM EST
1.530
+0.060 (4.08%)
After-hours: Mar 3, 2026, 4:44 PM EST
Medicus Pharma Stock Forecast
MDCX's stock price has decreased by -63.16% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Medicus Pharma stock have an average target of 23.5, with a low estimate of 20 and a high estimate of 27. The average target predicts an increase of 1,498.64% from the current stock price of 1.47.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 15, 2025.
Analyst Ratings
The average analyst rating for Medicus Pharma stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +1,736.73% | Dec 15, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +1,736.73% | Nov 17, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +1,736.73% | Nov 13, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +1,736.73% | Oct 29, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +1,736.73% | Oct 22, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.94
from -1.16
EPS Next Year
-0.80
from -1.94
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.97 | -0.51 | ||||
| Avg | -1.94 | -0.80 | ||||
| Low | -1.89 | -1.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.